Blood:KLF4-DYRK2介导通路调节CML干细胞的自我更新

2020-01-02 不详 MedSci原创

中心点:KLF4丢失可通过去DYRK2基因抑制损伤CML干/祖细胞的自我更新和存活。稳定DYRK2蛋白可通过耗竭c-Myc和激活p53抑制白血病干/祖细胞的存活和自我更新。摘要:白血病干细胞是一种罕见的具有原始祖细胞表型的群体,它可以通过一种尚不清楚的自我更新机制来启动、维持和再现白血病。近期,研究人员发现在慢性髓系白血病(CML)样骨髓增值性肿瘤的小鼠模型中,Krüppel样因子4(KLF4)可

中心点:

KLF4丢失可通过去DYRK2基因抑制损伤CML干/祖细胞的自我更新和存活。

稳定DYRK2蛋白可通过耗竭c-Myc和激活p53抑制白血病干/祖细胞的存活和自我更新。

摘要:

白血病干细胞是一种罕见的具有原始祖细胞表型的群体,它可以通过一种尚不清楚的自我更新机制来启动、维持和再现白血病。

近期,研究人员发现在慢性髓系白血病(CML)样骨髓增值性肿瘤的小鼠模型中,Krüppel样因子4(KLF4)可通过抑制具有白血病启动能力的白血病干细胞/祖细胞的保存抑制机制,促进病程进展。在BCR-ABL1+ CD150+细胞系阴性Sca-1+ c-Kit+白血病细胞中,敲除Klf4基因可通过影响存活和自我更新严重破坏BCR-ABL1(p210)诱导的CML的维持。

在机制上,在白血病干/祖细胞中,KLF4抑制Dyrk2基因;因此,KLF4丢失可导致双特异性酪氨酸(Y)磷酸化调节激酶2(DYRK2)水平升高,这与通过耗竭c-Myc蛋白和p53激活抑制存活和自我更新相关。除了转录调控,通过维生素K3抑制泛素E3连接酶SIAH2来稳定DYRK2蛋白也可促进小鼠和人CML干/祖细胞的凋亡和自我更新受阻。

总而言之,本研究表明DYRK2是一种分子检查点,调控p53和c-Myc介导的具有白血病启动能力的CML细胞的存活和自我更新的调节,可作为靶点用于CML治疗。

原始出处:

Chun Shik Park, et al.A KLF4-DYRK2–mediated pathway regulating self-renewal in CML stem cells.Blood.  November 28, 2019.

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2024517, encodeId=9b47202451e81, content=<a href='/topic/show?id=6969636efb' target=_blank style='color:#2F92EE;'>#DYRK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6367, encryptionId=6969636efb, topicName=DYRK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Feb 28 08:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659321, encodeId=98e91659321e0, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Sat Jul 25 04:04:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783265, encodeId=0a2b1e8326542, content=<a href='/topic/show?id=e1ac4901bb' target=_blank style='color:#2F92EE;'>#CML干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4901, encryptionId=e1ac4901bb, topicName=CML干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 07 16:04:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025380, encodeId=91e61025380a9, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sun Jan 05 15:04:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488714, encodeId=49d71488e1422, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4899, encryptionId=20b24899a7, topicName=CML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e8470831, createdName=wangbingxhy, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542790, encodeId=88601542e9089, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2024517, encodeId=9b47202451e81, content=<a href='/topic/show?id=6969636efb' target=_blank style='color:#2F92EE;'>#DYRK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6367, encryptionId=6969636efb, topicName=DYRK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Feb 28 08:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659321, encodeId=98e91659321e0, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Sat Jul 25 04:04:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783265, encodeId=0a2b1e8326542, content=<a href='/topic/show?id=e1ac4901bb' target=_blank style='color:#2F92EE;'>#CML干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4901, encryptionId=e1ac4901bb, topicName=CML干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 07 16:04:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025380, encodeId=91e61025380a9, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sun Jan 05 15:04:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488714, encodeId=49d71488e1422, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4899, encryptionId=20b24899a7, topicName=CML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e8470831, createdName=wangbingxhy, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542790, encodeId=88601542e9089, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2024517, encodeId=9b47202451e81, content=<a href='/topic/show?id=6969636efb' target=_blank style='color:#2F92EE;'>#DYRK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6367, encryptionId=6969636efb, topicName=DYRK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Feb 28 08:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659321, encodeId=98e91659321e0, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Sat Jul 25 04:04:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783265, encodeId=0a2b1e8326542, content=<a href='/topic/show?id=e1ac4901bb' target=_blank style='color:#2F92EE;'>#CML干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4901, encryptionId=e1ac4901bb, topicName=CML干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 07 16:04:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025380, encodeId=91e61025380a9, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sun Jan 05 15:04:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488714, encodeId=49d71488e1422, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4899, encryptionId=20b24899a7, topicName=CML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e8470831, createdName=wangbingxhy, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542790, encodeId=88601542e9089, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2024517, encodeId=9b47202451e81, content=<a href='/topic/show?id=6969636efb' target=_blank style='color:#2F92EE;'>#DYRK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6367, encryptionId=6969636efb, topicName=DYRK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Feb 28 08:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659321, encodeId=98e91659321e0, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Sat Jul 25 04:04:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783265, encodeId=0a2b1e8326542, content=<a href='/topic/show?id=e1ac4901bb' target=_blank style='color:#2F92EE;'>#CML干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4901, encryptionId=e1ac4901bb, topicName=CML干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 07 16:04:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025380, encodeId=91e61025380a9, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sun Jan 05 15:04:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488714, encodeId=49d71488e1422, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4899, encryptionId=20b24899a7, topicName=CML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e8470831, createdName=wangbingxhy, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542790, encodeId=88601542e9089, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
    2020-01-05 独孤立克

    干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2024517, encodeId=9b47202451e81, content=<a href='/topic/show?id=6969636efb' target=_blank style='color:#2F92EE;'>#DYRK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6367, encryptionId=6969636efb, topicName=DYRK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Feb 28 08:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659321, encodeId=98e91659321e0, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Sat Jul 25 04:04:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783265, encodeId=0a2b1e8326542, content=<a href='/topic/show?id=e1ac4901bb' target=_blank style='color:#2F92EE;'>#CML干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4901, encryptionId=e1ac4901bb, topicName=CML干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 07 16:04:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025380, encodeId=91e61025380a9, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sun Jan 05 15:04:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488714, encodeId=49d71488e1422, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4899, encryptionId=20b24899a7, topicName=CML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e8470831, createdName=wangbingxhy, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542790, encodeId=88601542e9089, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
    2020-01-04 wangbingxhy
  6. [GetPortalCommentsPageByObjectIdResponse(id=2024517, encodeId=9b47202451e81, content=<a href='/topic/show?id=6969636efb' target=_blank style='color:#2F92EE;'>#DYRK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6367, encryptionId=6969636efb, topicName=DYRK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Feb 28 08:04:00 CST 2020, time=2020-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659321, encodeId=98e91659321e0, content=<a href='/topic/show?id=7287861e2ed' target=_blank style='color:#2F92EE;'>#自我更新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86172, encryptionId=7287861e2ed, topicName=自我更新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=764624964499, createdName=xsm926, createdTime=Sat Jul 25 04:04:00 CST 2020, time=2020-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783265, encodeId=0a2b1e8326542, content=<a href='/topic/show?id=e1ac4901bb' target=_blank style='color:#2F92EE;'>#CML干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4901, encryptionId=e1ac4901bb, topicName=CML干细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Mon Sep 07 16:04:00 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025380, encodeId=91e61025380a9, content=干细胞是热点,但是进入临床仍然需要时间和临床疗效验证哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=独孤立克, createdTime=Sun Jan 05 15:04:00 CST 2020, time=2020-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488714, encodeId=49d71488e1422, content=<a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4899, encryptionId=20b24899a7, topicName=CML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3e8470831, createdName=wangbingxhy, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542790, encodeId=88601542e9089, content=<a href='/topic/show?id=b37e1052940' target=_blank style='color:#2F92EE;'>#KLF4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10529, encryptionId=b37e1052940, topicName=KLF4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20e513483998, createdName=124986d2m13暂无昵称, createdTime=Sat Jan 04 06:04:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]

相关资讯

Circ Res:血管重塑血管外膜sca1阳性祖细胞的来源及功能研究

血管外膜位于血管壁外层,是包含滋养微血管、神经、成纤维细胞、免疫细胞和原位祖细胞的复合层。外膜祖细胞表达干细胞标记物Sca1和CD34(外膜sca1阳性祖细胞简称AdvSca1),具有体外分化为多个谱系的潜力,并且可能促进体内内膜损伤。近日,美国学者发表题为《分化型平滑肌细胞依赖Klf4产生原位血管外膜祖细胞亚群》的研究文章于血管研究顶级期刊Circulation Research。越来越多的数据

CLIN CANCER RES:KLF4抑制STK33活化及胃癌转移

肿瘤异常STK33表达与特定侵袭性有关。但是,其在胃癌中的表达、临床意义和生物学功能尚不清楚。CLIN CANCER RES近期发表了一篇文章,研究STK33在胃癌中的表达及功能,阐述KLF4/STK33信号通路的临床意义。

Circulation:Krüppel样因子4调节Ch25h和LXR减轻动脉粥样硬化

动脉粥样硬化是包括血管壁细胞(例如内皮细胞[ECs])以及循环和驻留的免疫原性细胞(如单核细胞/巨噬细胞)在内的多种细胞参与的炎性疾病。作为肝脏X受体(LXR)的配体,SREBP2(甾醇调节元件结合蛋白2)的抑制剂,25-羟基胆固醇及其催化酶胆固醇-25-羟化酶(Ch25h)在调节细胞炎症状态中发挥着重要的作用,且在ECs和单核细胞/巨噬细胞中胆固醇的生物合成中发挥着重要作用。研究人员采用生物信息

Blood:DYRK2,CML的新潜在治疗靶点!

近期,Chun Shik Park等人发现KLF4可通过抑制具有白血病启动能力的白血病干细胞/祖细胞的抑制机制,促进慢性髓系白血病(CML)样骨髓增生性肿瘤小鼠模型的疾病进展。敲除klf4基因可通过损害BCR-ABL1+CD150+LSK白血病细胞的存活和自我更新,从而严重破坏BCR-ABL1(p210)诱导的CML的维持。

Oncotarget:结直肠癌治疗中又一潜在靶标miR-543

microRNAs作为转录后调控的关键分子在许多生理和病理过程中有着重要作用,miR-543是一个与癌症相关的mircoRNA,研究表明miR-543的表达与一些癌症的发展相关。

OncoTargets and Therapy:KLF4可预测晚期乳腺癌新辅助化疗的疗效

OncoTargets and Therapy:KLF4可预测晚期乳腺癌新辅助化疗的疗效 研究背景:对于局部晚期乳腺癌患者,新辅助化疗(NAC)可增加切除率和获得保乳手术机会,NAC达到病理完全缓解(PCR)的患者有更好的预后,然而一部分患者却对化疗无效,因此研究可预测NAC疗效的分子标记物对于指导临床治疗有十分重要的作用。以往的研究表明转录因子KLF4与肿瘤干细胞(CSCs)的维持以及对肿